Pexidartinib Hydrochloride and Ranitidine Tablets
Determining the interaction of Pexidartinib Hydrochloride and Ranitidine Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.ADJUST DOSING INTERVAL: Coadministration with acid-reducing agents may significantly decrease the bioavailability and therapeutic effects of pexidartinib. The proposed mechanism is a pH-dependent reduction in drug dissolution and/or absorption. Concomitant administration of esomeprazole, a proton pump inhibitor, decreased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 55% and 50%, respectively. The effect of coadministration with an H2-receptor antagonist or locally-acting antacids on pexidartinib pharmacokinetics is unknown. MANAGEMENT: If acid-suppression therapy is required, pexidartinib should be administered at least 2 hours before or 10 hours after taking an H2-receptor antagonist or 2 hours before or 2 hours after taking a locally-acting antacid. Concomitant use of pexidartinib with proton pump inhibitors should be avoided. References "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Professional:ADJUST DOSING INTERVAL: Coadministration with acid-reducing agents may significantly decrease the bioavailability and therapeutic effects of pexidartinib. The proposed mechanism is a pH-dependent reduction in drug dissolution and/or absorption. Concomitant administration of esomeprazole, a proton pump inhibitor, decreased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 55% and 50%, respectively. The effect of coadministration with an H2-receptor antagonist or locally-acting antacids on pexidartinib pharmacokinetics is unknown.
MANAGEMENT: If acid-suppression therapy is required, pexidartinib should be administered at least 2 hours before or 10 hours after taking an H2-receptor antagonist or 2 hours before or 2 hours after taking a locally-acting antacid. Concomitant use of pexidartinib with proton pump inhibitors should be avoided.
- "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Generic Name: pexidartinib
Brand name: Turalio
Synonyms: Pexidartinib
Generic Name: ranitidine
Brand name: Zantac
Synonyms: Ranitidine
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Pexidartinib Hydrochloride-Ranitidine Tablets and Capsules
- Pexidartinib Hydrochloride-Ranolazine
- Pexidartinib Hydrochloride-Ranolazine ER Tablets
- Pexidartinib Hydrochloride-Rapaflo
- Pexidartinib Hydrochloride-Rapamune
- Pexidartinib Hydrochloride-Rapamune (Sirolimus Oral Solution)
- Ranitidine Tablets-Pfizerpen
- Ranitidine Tablets-Pharaon Tea
- Ranitidine Tablets-Pharmorubicin Pfs
- Ranitidine Tablets-Phazyme
- Ranitidine Tablets-Phazyme Liquid Gas Relief, Maximum Strength
- Ranitidine Tablets-Phena-Plus